Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Immunological Memory01:23

Immunological Memory

6.4K
Immunological memory, a pivotal pillar of the adaptive immune system, is responsible for the body's ability to remember and respond more swiftly and effectively to previously encountered pathogens. This remarkable feature is what makes vaccines so effective in preventing diseases.
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...
6.4K
Vaccinations01:51

Vaccinations

45.4K
Overview
45.4K
Development of Immunocompetence01:22

Development of Immunocompetence

467
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
467
Active versus Passive Immunity01:31

Active versus Passive Immunity

4.6K
Immunity, along with the ability to limit pathogen growth to prevent significant body tissue damage, can be gained either by (1) actively developing an immune response within the individual after exposure to a pathogen or after getting vaccinated or (2) passively transferring immune components from an immune individual to one who is nonimmune. Both these forms of immunity can be found naturally and in medical practices.
Active Immunity
Active immunity refers to the resistance one develops...
4.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of cross-stage, cross-species malaria CD8<sup>+</sup> T cell antigens.

Nature·2026
Same author

Maternal microchimerism at birth associates with reduced odds of non-malarial fever and respiratory tract infections in Tanzanian children.

PLOS global public health·2026
Same author

Mosquito direct skin feeding bioassay: 15 years of experience and a standardised approach in Mali.

Malaria journal·2026
Same author

Antibody levels to variant and conserved <i>Plasmodium falciparum</i> antigens predict reduction in parasite burden in Malian children.

Frontiers in immunology·2026
Same author

Sex-based differences in Plasmodium infection in the control groups of controlled human malaria infection trials in malaria-naive populations in the USA and the Netherlands: a pooled analysis.

The Lancet. Microbe·2026
Same author

Epitope-specific competitive ELISA predicts malaria transmission-blocking vaccine Pfs230D1 activity measured in standard membrane feeding assay.

JCI insight·2026

Related Experiment Video

Updated: Sep 22, 2025

Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination
08:13

Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination

Published on: January 20, 2019

21.9K

PfSPZ Vaccine learns a lesson.

Irfan Zaidi1, Patrick E Duffy1

  • 1Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD USA.

Med (New York, N.Y.)
|May 19, 2022
PubMed
Summary
This summary is machine-generated.

The PfSPZ malaria vaccine showed low efficacy in Kenyan infants, unlike in African adults. Differences in immune responses may explain this varied protection against malaria.

More Related Videos

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

10.9K
Application of Long-term cultured Interferon-&#947; Enzyme-linked Immunospot Assay for Assessing Effector and Memory T Cell Responses in Cattle
15:57

Application of Long-term cultured Interferon-γ Enzyme-linked Immunospot Assay for Assessing Effector and Memory T Cell Responses in Cattle

Published on: July 11, 2015

12.3K

Related Experiment Videos

Last Updated: Sep 22, 2025

Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination
08:13

Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination

Published on: January 20, 2019

21.9K
Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

10.9K
Application of Long-term cultured Interferon-&#947; Enzyme-linked Immunospot Assay for Assessing Effector and Memory T Cell Responses in Cattle
15:57

Application of Long-term cultured Interferon-γ Enzyme-linked Immunospot Assay for Assessing Effector and Memory T Cell Responses in Cattle

Published on: July 11, 2015

12.3K

Area of Science:

  • Immunology
  • Vaccinology
  • Infectious Diseases

Background:

  • Malaria remains a significant global health challenge, particularly in sub-Saharan Africa.
  • The PfSPZ vaccine, an attenuated whole organism malaria vaccine, has shown promise in adult populations.
  • Understanding vaccine efficacy variations across different demographic groups is crucial for malaria control.

Purpose of the Study:

  • To evaluate the efficacy of the attenuated whole organism PfSPZ Vaccine in infants in Kenya.
  • To investigate potential reasons for differential vaccine efficacy observed between infants and adults.

Main Methods:

  • Clinical trial of the PfSPZ Vaccine in Kenyan infants.
  • Comparative analysis of vaccine efficacy data from infant and adult trials.
  • Exploration of immunological differences between age groups.

Main Results:

  • The PfSPZ Vaccine demonstrated limited efficacy in preventing malaria infection in Kenyan infants.
  • Previous trials in African adults consistently reported significant protection against malaria.
  • Observed disparities in immune responses between infants and adults may correlate with vaccine outcomes.

Conclusions:

  • The efficacy of the PfSPZ Vaccine appears to be age-dependent, with lower effectiveness in infants compared to adults.
  • Further research into the immunological factors influencing vaccine response in different age groups is warranted.
  • Developing age-specific malaria vaccination strategies may be necessary for optimal disease control.